Spinocerebellar Ataxia Type 2 Clinical Trial
Official title:
Integrated Functional Evaluation of the Cerebellum
One of the main objectives of this project is to validate potential biological, clinical and/or imaging biomarkers in SCA patients through a multimodal assessment, for future ASOs trials.
Spinocerebellar ataxias (SCAs) are autosomal dominantly inherited neurological disorders, characterized by a predominant atrophy of the cerebellum and the brainstem. The most common forms are caused by abnormal CAG repeat expansions, encoding elongated polyglutamine (polyQ). Nowadays, no preventive or curative treatments are available but different therapeutic approaches are ongoing. Antisense oligonucleotides (ASOs) therapy showed promising results in Huntington disease (HD), a disease that shares with the SCAs the same mutational mechanism. ASOs are currently under development for SCAs. However, in SCAs, clinical scales as an only criteria to monitor a treatment are not appropriate because of the lack of sensitivity of change and the small number of patients available. The importance to dispose of outcome measures to inform about the efficacy of a treatment is fundamental as well as of new alternative designs to conduct a clinical trial in rare diseases with small sample sizes. A comprehensive, multimodal approach is hence needed to provide a translational and integrated overview of cerebellar dysfunction in polyQ SCAs over a year. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01470729 -
Biomarkers in Autosomal Dominant Cerebellar Ataxia
|
||
Active, not recruiting |
NCT03701399 -
Troriluzole in Adult Subjects With Spinocerebellar Ataxia
|
Phase 3 | |
Withdrawn |
NCT04301284 -
Study of CAD-1883 for Spinocerebellar Ataxia
|
Phase 2 | |
Active, not recruiting |
NCT04268147 -
Instrumented Data Exchange for Ataxia Study
|
||
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Completed |
NCT03347344 -
Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)
|
Phase 3 | |
Active, not recruiting |
NCT05826171 -
Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia
|
N/A | |
Completed |
NCT03120013 -
Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia
|
N/A | |
Not yet recruiting |
NCT03378414 -
Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
|
Phase 2 | |
Active, not recruiting |
NCT03408080 -
Open Pilot Trial of BHV-4157
|
Phase 3 | |
Completed |
NCT04153110 -
Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxia
|
N/A | |
Recruiting |
NCT01060371 -
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
|